NDAORALTABLET, CHEWABLE
Approved
Nov 2013
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
1
Data completeness
6/8 — Strong
VELPHORO (sucroferric oxyhydroxide) by Fresenius Kabi is phosphate chelating activity [moa]. Approved for hyperphosphatemia. First approved in 2013.
Drug data last refreshed Yesterday · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VELPHORO (sucroferric oxyhydroxide) is an oral chewable tablet phosphate binder approved by the FDA in November 2013. It works through phosphate chelating activity to reduce serum phosphorus levels in patients with chronic kidney disease. The product is indicated for phosphate control in patients on dialysis and represents a non-calcium, non-aluminum alternative in the phosphate binder class.
$0.5BPart D
9.1 years to LOEMechanism of Action
Phosphate Chelating Activity
Pharmacologic Class:
Phosphate Binder
Indications (1)
Clinical Trials (1)
Effect of Velphoro on Serum Phosphate and Albumin in Peritoneal Dialysis Patients
Started Feb 2020
17 enrolled
Peritoneal Dialysis ComplicationHyperphosphatemiaHypoalbuminemia
Why This Matters for Your Career
Worked on VELPHORO at Fresenius Kabi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.